Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.65 |
| ▸ | CES1 | P23141 | 4/20 | 0.65 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.62 |
| ▸ | PPARG | P37231 | 7/20 | 0.62 |
| ▸ | PPARD | Q03181 | 7/20 | 0.62 |
| ▸ | PPARA | Q07869 | 7/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.62 |
| ▸ | TSHR | P16473 | 5/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | TLR2 | O60603 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | FABP4 | P15090 | 2/20 | 0.62 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.62 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79563 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL56011 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL155222 | 1.00 | — | — | |
| SCHEMBL160220 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL4141832 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL54806 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL421576 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL41461 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL276881 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL205397 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | claimed |
| US-6787525-B1 | METHOD OF TREATING HIV INFECTIONS AND/OR CANCER DISEASES | SCHOTT HERBERT (DE) | 2004-09-07 | — | — | US | claimed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | claimed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | claimed |
| EP-1135401-B1 | GLYCERYL NUCLEOTIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | SCHOTT HERBERT (DE) | 2003-06-18 | — | — | EP | claimed |
| EP-1135401-A1 | GLYCERYL NUCLEOTIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | SCHOTT, Herbert (DE) | 2001-09-26 | — | — | EP | claimed |
| WO-2000034298-A1 | GLYCERYL NUCLEOTIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | SCHOTT HERBERT (DE) | 2000-06-15 | — | — | WO | claimed |
| US-5191071-A | Nonionic surfactants | NOVO NORDISK A/S (DK) | 1993-03-02 | — | — | US | claimed |
| CN-114449994-A | Cosmetic or dermatological composition for cleansing and/or removing cosmetics, comprising succinic acid, for preventing, reducing or eliminating skin defects, treating skin diseases and preventing, treating and combating excessive seborrhoeic disorders of the scalp | 罗盖特公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-107982082-B | Transparent shampoo composition | 日油株式会社 | 2021-12-31 | — | — | CN | disclosed |
| CN-107811880-B | Transparent shampoo composition | 日油株式会社 | 2021-12-31 | — | — | CN | disclosed |
| EP-2013240-B1 | PROCESS FOR THE PREPARATION OF CROSSLINKED NITROXIDE POLYMERS | PIOTREK CO LTD (JP) | 2017-05-31 | — | — | EP | disclosed |
| EP-0056992-A1 | Phosphorylated derivatives, pharmaceutical compositions containing such derivatives, and their use | CIBA-GEIGY AG (CH) | 1982-08-04 | — | — | EP | disclosed |
| EP-0034347-A2 | Derivatives of aldohexoses, intermediates, process for their production, preparations containing such compositions and their use | CIBA-GEIGY AG (CH) | 1981-08-26 | — | — | EP | disclosed |
| EP-0026746-A1 | Combinatory compositions for use in a method for enhancing the activity of antibiotics, antibiotic preparations having enhanced activity and process for their production | CIBA-GEIGY AG (CH) | 1981-04-08 | — | — | EP | disclosed |
| US-3936462-A | CNS DEPRESSANT, ANALGESIC | STERLING DRUG INC. (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | CES2 935/4885CES1 2798/4885GPR84 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.